Clinical Considerations for the Integration of Adjuvant Olaparib into Practice for Early Breast Cancer: A Canadian Perspective

Clinical Considerations for the Integration of Adjuvant Olaparib into Practice for Early Breast Cancer: A Canadian Perspective

With the recent Health Canada approval of olaparib for high-risk, HER2-negative early breast cancer, physicians are now facing the practical challenges of integrating olaparib into current management of triple-negative breast cancer (TNBC) and HR-positive, HER2-negative (HR+/HER2−) early breast canc...

Full description

Bibliographic Details
Main Authors: Jan-Willem Henning, Jean-François Boileau, Larissa Peck, Tom McFarlane
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Current Oncology
Subjects:
adjuvant therapy
BRCA
capecitabine
early-stage breast cancer
genetic testing
olaparib
Online Access:https://www.mdpi.com/1718-7729/30/8/556

Internet

https://www.mdpi.com/1718-7729/30/8/556

Similar Items